Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.53 |
| ▸ | RXRB | P28702 | 12/20 | 0.53 |
| ▸ | RXRG | P48443 | 8/20 | 0.53 |
| ▸ | RARB | P10826 | 7/20 | 0.53 |
| ▸ | RARG | P13631 | 7/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.49 |
| ▸ | RARA | P10276 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.38 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15617210 | 0.83 | RXRA (0.56) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL17914352 | 0.82 | RXRA (0.54) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20277839 | 0.80 | RXRA (0.53) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7560489 | 0.77 | RXRA (0.50) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7759680 | 0.76 | RXRA (0.69) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5359574 | 0.72 | RXRA (0.49) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7561241 | 0.72 | RXRA (0.49) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL17916279 | 0.72 | CYP26A1 (0.46) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL17916345 | 0.72 | CYP26A1 (0.46) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1615553 | 0.70 | RXRA (0.46) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| EP-2874999-B1 | NOVEL SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-9408793-B2 | Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-09 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20150190323-A1 | SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-09 | — | — | US | disclosed |
| EP-2874999-A1 | NOVEL SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014016507-A1 | NOVEL SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | CYP2B6, CYP26A1, CYP2A6 | RXRA 15/4885RXRB 12/4885RXRG 18/4885 |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | RXRA 935/4885RXRB 836/4885RXRG 663/4885 |
| US-20150190323-A1 | SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | CYP26A1, CYP21A2, CYP26B1 | RXRA 233/4885RXRB 242/4885RXRG 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.